Novartis announced that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy.
Swiss drug maker Roche has agreed to acquire US-based gene therapy company Spark Therapeutics in an all-cash deal worth around $4.3bn.
French pharma company Ipsen has agreed to acquire Canada-based Clementia Pharmaceuticals in an all-cash deal worth up to $1.3bn to boost its rare disease portfolio.
Urovant Sciences, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, announced it has entered into a debt financing agreement with Hercules Capital for up to $100m.
AbbVie and Voyager Therapeutics will engage in the development of vectorized antibodies to treat Parkinson's disease and other synucleinopathies, under a deal worth over $1.5bn.
Morphic Therapeutic, a biotechnology company developing oral integrin therapies, has entered into a research and development collaboration with Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.
Merck has signed an agreement to acquire late-stage immunotherapy firm, Immune Design, in a deal valued at around $300m.
Peloton Therapeutics, a drug discovery and development company advancing oral medicines for cancer and other serious conditions, has announced the closing of an oversubscribed $150 million Series E financing.
Knight Therapeutics, a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription pharmaceutical products and Moksha8, a specialty pharmaceutical company focused on licensing and marketing innovative and established therapeutics in Latin America, announced the closing of a strategic financing agreement for up to $125m.
Decipher Biosciences (formerly GenomeDx) has announced a research collaboration with Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, to apply genomic tumor profiling using the Decipher assay and GRID software to identify prostate cancer patients on active surveillance who may benefit most from treatment with sipuleucel-T.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.